SCHEMBL24258053

SCHEMBL24258053

O=c1ccc(-c2noc(Cc3ccc(Cl)c(Cl)c3)n2)c[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.49
ERCC4 Q92889 1/20 0.49
KCNH2 Q12809 1/20 0.48
MAPK1 P28482 5/20 0.48
TSHR P16473 5/20 0.48
TDP1 Q9NUW8 4/20 0.48
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
ALOX15 P16050 1/20 0.44
RAB9A P51151 2/20 0.43
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
GAA P10253 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PNP P00491 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258072 0.86 MAPK1 (0.58) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL26004727 0.86 MAPT (0.47) ERCC1ERCC4KCNH2MAPK1TSHR
SCHEMBL24258021 0.85 ERCC1 (0.48) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL24258039 0.84 ERCC1 (0.45) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL24258083 0.83 ERCC1 (0.43) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL24258048 0.81 TDP1 (0.57) MAPK1TSHRTDP1KMT2AMEN1
SCHEMBL24258084 0.81 S1PR1 (0.58) MAPK1TSHRTDP1KMT2AMEN1
SCHEMBL24258023 0.81 S1PR1 (0.43) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL26006746 0.80 ERCC1 (0.39) ERCC1ERCC4KCNH2MAPK1TSHR
SCHEMBL24258040 0.79 KCNH2 (0.48) ERCC1ERCC4KCNH2MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 ERCC1 2832/4885ERCC4 1843/4885KCNH2 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.